Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Moderate-intensity aerobic exercise improves physical fitness in bethlem myopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Collagen XII myopathy with rectus femoris atrophy and collagen XII retention in fibroblasts

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fatal kakeksi ved mitokondriel neurogastrointestinal encefalomyopati.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A population-based and cross-sectional study of the long-term prognosis in multifocal motor neuropathy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Variations in muscle strength and function have not been studied in patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy whose treatment regimen has been changed from intravenous to subcutaneous immunoglobulin (IVIg to SCIg).

METHODS: In a prospective, open-label study, patients were changed from monthly IVIg to weekly SCIg. The primary endpoint was variation in isokinetic muscle strength (cIKS). Secondary endpoints were variations in Medical Research Council (MRC) score, grip strength (GS), 9-hole-peg test (9-HPT), and 40-meter-walk test (40-MWT).

RESULTS: The coefficient of variance of cIKS during the IVIg and SCIg treatment periods was unchanged (mean ± SD: 6.97 ± 4.83% vs. 5.50 ± 3.13%, P = 0.21). The variations in the 9-HPT and 40-MWT were significantly lower in the SCIg group (P = 0.01 and P = 0.005, respectively).

CONCLUSION: When therapy was changed from IVIg to SCIg, fluctuation of muscle strength was unchanged, but performance fluctuations were diminished. Muscle Nerve, 2017.

Original languageEnglish
JournalMuscle and Nerve
Volume57
Issue number4
Pages (from-to)610-614
ISSN0148-639X
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 52415771